• Innovative Eye Science

    Your vision is our focus

    Play
    Select Video
  • Play
    Select Video
  • Play
    Select Video
  • Play
    Select Video

At Inotek, we're working to define the future of glaucoma treatment.

Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye.

Use the links above to view videos of our key leaders and contributors discussing Inotek's mission, vision, and the potential therapeutic value of our lead product candidate, trabodenoson.

Inotek recognizes World Glaucoma Week March 12-18 and stands with the glaucoma community in striving to halt the second leading cause of blindness. Please visit http://www.wgweek.net/about-world-glaucoma-week/ for more information.

A New Class of Glaucoma Therapy

Our most advanced product candidate, trabodenoson, is a highly selective adenosine mimetic and the first potential treatment for glaucoma of its kind.

Adenosine is an important molecule occurring naturally in the body that participates in a wide variety of physiological and pathological processes. Inotek’s scientists have deconstructed adenosine’s complex biology to isolate the protective activity of the molecule, and subsequently to build it into novel therapeutics.

Read More >

News

Inotek Pharmaceuticals Corporation Reports Fiscal Year 2016 Financial Results and Operational Highlights

LEXINGTON, Mass.--(BUSINESS WIRE)--Mar. 16, 2017-- Inotek Pharmaceuticals Corporation (NASDAQ:ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today reported financial results and operational highlights for the fiscal year ended December 31, 2016. “In 2016, Inotek completed the Phase 3 MATrX-1 clinical trial of trabodenoson...

Read More >